KROS
NASDAQ · Biotechnology
Keros Therapeutics Inc
$10.96
-0.16 (-1.44%)
Open$11.10
Previous Close$11.12
Day High$11.41
Day Low$10.68
52W High$22.55
52W Low$9.12
Volume—
Avg Volume410.7K
Market Cap356.76M
P/E Ratio5.54
EPS$1.54
SectorBiotechnology
Analyst Ratings
Buy
15 analysts
Price Target
+79.7% upside
Current
$10.96
$10.96
Target
$19.70
$19.70
$13.49
$19.70 avg
$20.36
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.46M | 4.38M | 103.26M |
| Net Income | -129,655,630 | -207,966,613 | -15,524,708 |
| Profit Margin | -5,277.6% | -5,013.7% | -15.0% |
| EBITDA | -144,858,636 | -245,260,567 | -22,220,211 |
| Free Cash Flow | — | — | -17,331,210 |
| Rev Growth | -43.9% | -43.9% | +11.8% |
| Debt/Equity | — | — | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |